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Summary: A commercially available luminescence enhanced enzyme immunoassay (Amerlite — Amersham
International) for carcinoembryonic antigen (CEA) was compared with an established enzyme immunoassay
(Monoclonal 1-step Assay — Abbott Laboratories). A reference ränge for healthy blood donors (n = 272)
was established for both kits. The blood donors were not separated into smokers and non-smokers, but were
excluded from the reference group if they showed abnormal aminotransferase or -glutamyltranspeptidase
serum values. Twenty eight donors were excluded in this way. The test group consisted of 130 known tumour
patients, and included pre- and post-operative serum samples. Normal and elevated CEA values were present.
All sera were negative for HBsAg, anti-HBsAg and anti-HIV äs determined with commercial enzyme
immunoassays used routinely in the blood bank. **
The luminescence enhanced immunoassay gave rise to a reference ränge (95% confidence limits) of less than
3.91 g/l in comparison with the enzyme immunoassay, which had a reference ränge of less than 4.12 g/l.
The proportion of elevated values in the tumour patient group was 37/130 for the luminescence enhanced
enzyme immunoassay and 28/130 for the enzyme immunoassay.
The correlation of values from both methods in the blood donor group was good (r = 0.771, n = 272). The
CEA levels found in the tümötir patient group differed significantly when measured in both kits (Wilcoxon
matched-pair signed rank test ·— c-alpha = —6.52, p < 0.01, n = 130), the Amersham kit giving the higher
results (median values — Abbott 2.35 ^/l, Amersham 2.50 g/l).
Although the CEA coticenträtions in the blood donor group were similar for both kits (median values —
Abbott 1.12 £ , Amershain 0.92 g/l), the Abbott kit gave significantly higher results statistically (Wilcoxon
matched^pair signed rank test — c-alpha = —3.55, p < 0.01, n == 272).
From dilution studies, the lower limit öf detection for both assays was set at 0.25 g/l CEA in serum, all
values below this being given äs not detectable.
As in the case of mäny other kits, the Standards could not be interchanged, although both were calibrated
against the international reference prepafation WMO 73/601.
The luminescence enhanced enzyme immunoassay can be included in the list of non-isotopic immunoassays
for CEA, although, like its competitors, it can only be used in the follow-up of tumour patients, and not äs
a screening test.
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Introduction
Although the first immunoassays using luininescent
labels were published over a decade ago (1), the
commercial exploitation of these methods has only
recently led to the production of immunoassay kits
using luminescent detection.
This brief communication reports the preliminary
performance of a luminescence enhanced enzyme im-
munoassay for the determination of carcinoem-
bryonic antigen (CEA). The method used for the
routine CEA determination, an enzyme immunoas-
say, was used äs a comparison (2).
Serum samples were obtained from healthy blood
donors and from known tumour-bearers.
Horseradish peroxidase was used äs label in both
cases, the enzyme immunoassay using 0-phenylene
diamine äs chromogen, the luminescence enhanced
immunoassay having an aryl hydrazide and an enhan-
cer äs luminogen. In both cases, the peroxidase func-
tioned äs an enzyme, the signal being proportional
to the amount of enzyme bound to the antigen-
antibody complex, i.e. to the amount of nascent
oxygen produced. This is in contrast to "conven-
tional" chemiluminescence immunoassays using aryl
hydrazide labels, where the hydrogen peroxide is in
excess, and the amount of immobilised luminogen
determines the light Output (3).
Materials and Methods
Apparatus and Kits
The enzyme immunoassay was purchased from Abbott Diag-
nostics (Wiesbaden Delkenheim, D) and was the monoclonal
l-step CEA-EIA kit. The assay was perfonned manually and
was measured in a microprocessor-controlled spectropho-
tometer (Quantum I — Abbott).
The luminescence enhanced immunoassay, supplied by Amer-
sham Buchler (Braunschweig, D), was the Amerlite CEA mono-
clonal antibody assay. Pipetting of samples was performed
manually, other steps being performed automatically. The
Amerlite System was a closed System äs far äs measurement
and data-processing were concerned. At the time of writing,
laboratory-own assays could not be perfonned using the sys-
tem.
The Abbott kit used the familiär ball and tray System, while
the Amerlite kit used coated well-strips which were fitted into
microtitre plates.
Samples
Blood donors were chosen äs the reference group, excluding
those who had abnormal aminotransferase and -
glutamyltranspeptidase values. All were negative for HBsAg,
anti HBsAg and anti HIV, äs determined by modern enzyme
immunoassays. Twenty eight out of 300 blood donors were
excluded from the study äs a result of the above screening
procedure. No discrimination was made between smokers and
non-smokers.
Serum from tumour patients was taken before and after Opera-
tion, no discrimination being made in the 130 patients studied.
The sera inclüded normal and clevated CEA concentrations.
Statistics
Non-parametric statistics were used throughout, äs the distribu-
tion of data in both groups was non-Gaussian. Tests used
inclüded the Mann-Whitney U-test'foith z-transformation and
the Wilcoxon signed rank test for matched pairs with c-alpha
calculation. The confldence limits for each group were given
äs the relevant percentile together with the median value. The
ratio mean/median was used äs an index of the data distribu-
tion. In all cases, the enzyme immunoassay (Abbott) was
entered äs x, the luminescence enhaneed enzyme immunoassay
(Amersham) äs y.
Results
The assay schemes are shown in tables l a and l b.
The distribution of serum concentrations in 272
healthy blood donors are shown in table 2 a, those
for the 130 tumour patients in table 2b. Table 2c
shows the correlation between both groups. Relevant
quality control parameters are given in table 3. The
light index values of the Standard curve from the
luminescence enhanced enzyme immunoassay are
shown in table 4 a. (The light index values of the
samples reflect the light intensity of the peroxidase-
lüminogen mixture in each well. They act äs a quality
control parameter inasmuch äs when they lie outside
a defined region, the latter being given by the prö-
ducer, accuracy and precision can no longer be guar-
anteed.) Although the light intensity decreases with
time, due to the depletion of Substrate and/or inacti^
vation of the peroxidase,> the values read off the
Standard curve were stable over 60 minutes after
addition of the signal reagent, even though the print-
out showed the flag "pöor cürVe" when the light
index feil below the lower limit of acceptance, which
in this case was 3.0. These results are summarised in
table 4b. Concurrence of values of samples measured
in both kits are shown for the 130 tumour patients
in table 5. Table 6 a shows the effect of diluting the
first Standard with the zero Standard to attempt to
define the lower detection limit of each assay. In the
case of the Amerlite assay, this was non-linear. Table
6 b shows the effect of measuring the Standards and
control sera from one kit äs samples in the contfa-
lateral kit. Table 6c shows the results of diluting
the Amersham 3 §/1 Standard with a serum which
repeatedly gave an undectable value in the Abbott
assay. After cörrectmg the 1:2 dilution for an "ex-
ogenous CEA" pf 0.04 §/1, the expected values for
the serial dilution were obtained down to ca. 0.2 §/1.
The lower limits of detection were set at 0.25 §/1,
all values below this being recorded äs not deteetable.
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Tab. l a. Assay scheme for the Abbott CEA-EIA monoclonal
(l-Step) enzyme immunoassay kit.
50 μ! sample/Standard
200 μΐ anti-CEA peroxidase conjugate
l anti-CEA coated ball
Incubate 60 min at 45 °C
Wash with 2 χ 5 ml water
Transfer beads to 75 χ 12 mm test tubes
Add 300 μΐ o-phenylene diamine solution
Incubate 30 min at ambient temperature
Add l ml l mol/1 sulphuric acid, vortex and measure at 492 nm.
Tab. 2 a. Distribution of CEA values in serum from 272 healthy
blood donors.
Parameter
2.5 Percentile
16 Percentile
Medi n (50 percentile)
84 Percentile
97.5 Percentile
mean
inean/median
Abbott EIA
n.d.
0.22 μ§/1
1.12
2.50
4.12
1.40 μg/l
1.25
Amersham LEIA
n.d.
n.d.
0.92 \igl\
2.28
3.91
1.31 μδ/1
1.42
Tab. l b. Assay scheme for Amersham Amerlite CEA assay
(monoclonal) assay kit.
100 μΐ assay reagent
100 μΐ sample/Standard
Incubate 120 min at 37 °C
Wash on Amerlite washer
200 μΐ conjugate reagent (anti-peroxidase)
Incubate and wash s above
250 μΐ signal reagent
Read off in Amerlite analyser 2—20 min after signal reagent
addition
Tab. 2 b. Distribution of CEA serum levels in 130 tumour
patients.
Parameter Abbott EIA Amersham LEIA
Disc ssion
The combination of an enzyme label and luminogen
s signal has been described for both dehydrogenases
(4) and for peroxidases (l, 5). The enhancement and
stabilisation of the light signal is system-specific and
cannot be transferred to pther Systems, even when
these use the same components in a different assay
form (3).
The enhancement and stabilising Systems have been
patented (5) s far s the peroxidase/acykaryl hydra-
zide system is concerned. As the peroxidase used in
the Amerlite kit serves s an enzyme, and not s a
"one-ofF' catalyst s in the conventional chemil mi-
nescence assay (6), the light signal depends upon
the aetivity of the enzyme. The light signal can be
enhanced by addition of compounds such s 4-iodo-
phenol and ZMuciferin (5).
Tables 4 a and 4b show that although the light inten-
sity decreases with time, useable Standard curves are
produced, even for times well in excess of those given
by the manufacturer between addition of signal re-
agent and measurement.
The values from both kits correlate well with each
other, s can be seen in tables 2a-2c, although
aberrant values can occur (tab. 5) in which one kit
2.5 Percentile n. d. 0.32 μg/l
16 Perdentile n.d. 1.10
Medi n (50 percentile) 2.35 μg/l 2.50
84 Percentile 5.87 5.56
97.5 Percentile 41.4 38.4
mean 11.2 11.5
mean/median 4.78 4.57
Tab. 2c. Correlation data for the blood donors — x-values =
Abbott, y-values = Amersham. Regression line y =
a + bx and χ = a + by.
r = 0.771, n = 272
a^ = 0.108, b^ = 0.888
axy = 0.493, bxy = 0.670
Wilcoxon signed rank test (Abbott vs Amersham)
Blood donors -r c-Alpha = —3.55, n = 254 (18 pairs dis-
carded — no rank difference) p <0.01
Tumour patients - c-Alpha = + 6.45, n = 123 (7 pairs
discarded — no rank difference) p <0.01
key:
n. d. — under detection limit
EIA — enzyme immunoassay, LEIA — Luminescence en-
hanced enzyme immunoassay.
gives Values inside the established reference r nge,
whereas the other one gives elevated values. Statisti-
cally speaking, the results from both kits differed
significantly, which was reflected for example by the
difference in the reference ranges.
Both kit protocols contained tables of expected values
for healthy and ill patients. For the Amersham kit,
data provided on 300 blood donors, including smo-
kers and non-smokers, showed that 98.6% had values
under 5.0 μg/l. This coincides well with the values
found in this study (98.4% of values less than 5 μg/l).
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Tab. 3. Intra- and interassay quality control data.
Intra-assay data.
Abbott EIA — mean coefficient of Variation from compound
precision profiles from 30 assays (n = 527 data pairs, concen-
tration ränge 0.3-10 g/l) = 5.75%.
Amersham LEIA — mean coefficient of Variation from com-
pound precision profiles from 20 assays (n = 344 data pairs,
concentration ränge 0.3-10 g/l) = 2.97%.
Interassay data
Parameter Abbott Amersham
Serum 1 mean 2.24 g/l 2.81 g/l
CV 7.14% 4.84%
n 30 20
Serum 2 mean 9.84 g/l 10.9 g/l
CV 5.89% 4.30%
n 30 20
Serum 3 mean 44.6 g/l 42.0 g/l
CV 5.77% 4.33%
n 30 20
For details about precision profiles — see 1. c. (2)
Tab. 4 a. Light index values of the Amersham LEIA for the
Standard curve. Time interval from signal reagent
addition 2—60 minutes.
Standard Signal
2 min 5 min 20 min 40 min 60 min
0 0.038 0.039 0.034 0.026 0.025
3 0.194 0.204 0.168 0.084 0.054
6 0.500 0.520 0.419 0.237 0.145
12 0.778 0.780 0.641 0.399 0.244
25 2.18 2.17 1.77 1.24 0.784
60 4.32 4.26 3.51 2.60 1.68
Light index 4.34 4.35 3.57 2.61 1.69
The 40 and 60 minute read-outs gave the flag "poor curve" äs
a warning, äs the light-index feil under the limit set in the
Programme (here for CEA 3.00)
Tab. 4b. Correlation of the CEA-values compared with the 5-
minute values.
n = 84 wells in each case, 5 min values äs
5 vs 20 min — .
r = 0.999, ay, = -0.259, by, = 1.02, axy = 0.259, b^ = 0.979
5 vs 40 min —
r = 0.999, ay, = -0.324, bxy = 1.03, axy = 0.324, bxy = 0.965
5 vs 60 min —
r = 0.999, ay* = -0.338, b^ = 1.03, axy = 0.339, bxy = 0.969
The values were statistically significant in each case (p < 0.001),
but this had no clinical implications and showed that differences
were due to curve fitting and not to individual differences in
the Signals from each well.
Tab. 5. Concurrence of values in the tumour patient sera äs
evaluated by both assays, using the reference ranges
established in tab. 2 a.
Abbott normal, Amersham normal 87
Abbott elevated, Amersham normal 6
Abbott normal, Amersham elevated 15
Abbott elevated, Ämersham elevated 22
·· r
Discrepancies occurred in 17% of the sera tested.
Tab. 6 a. Dilution of the first Standard with the zero Standard
to deflne the lower limit of detection of the assay.
Expected Found Recovery
value vahie %
Amersham LEIA 3.00 3.00 100
1.50 1.82 121
0.75 0.92 131
0.38 0.51 134
0.19 0.31 163
0.09 0.18 200
0 0.05 /
Abbott EIA 4.00 3.89 97
2.00 1.90 95
1.00 0.93 93
0.67 0.67 100
0.50 0.54 108
0.33 0.37 121
0.17 n.d. /
0 n.d. /
Tab. 6 b. Standards and control sera measured äs unknowns in
the contralateral kit.
Nominal Found
cöncentration concentration
Amersham LEIA 0 n. d.
Abbott Standards 4.00 6.32
30.0 40.5
80.0 over 60
Abbott control sera 1.60-3.60 1.95
13.8 -20.8 16.7
Amersham control sera 4.00— 5.40 4.70
10.1 -14.3 13.2
26.4 -36.0 32.6
Abbott EIA 0 n. d.
Amersham Standards 3.00 2.35
6. 3.54
12.0 7.38
25.6 18.0
60.0 0.46
Abbott control sera 1.60- 3,60 2.46
13.8 -20.8 18.9
Amersham control sera 4.00 -^ 5.40 4.20
10.1 -14.3 12.2
26.4 -36.0 28.4
Key: n. d. — below limit of detection of the assay.
i
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Tab. 6 c. Dilution of the first Standard of the Amerlite kit with
a patient serum with no detectable CEA in the Abbott
EIA.
Dilution
factor
lin 1
2
4
8
16
32
64
Expected
conccntration
W/1
3.0
1.5
0.75
0.38
0.19
0.10
0.05
Found
concentration
Mg/1
3.98
1.52
0.81
0.43
0.24
0.16
0.12
Recovery
%
99
102 (100)
108 (103)
113(103)
126 (100)
160 (120)
240 (160)
Values are the mean 5 dihition curves performed in duplicate.
The values in parentheses are those obtained by correcting the
l in 2 dihition by 0.04 μ§/1, i. e. accepting the diflerence between
found and expected values to be correct.
The assay appears to be able to measure correctiy down to 0.2
Mg/l-
The Abbott kit gave values under 5.0 μ§/1 for all
healthy non-smokers (n = 430), and for 640 healthy
smokers and non-smokers 98.6% of all values were
under 5.0 μ§/1. In this study, 98.8% of the reference
group had values under 5.0 μg/l with the Abbott kit.
The sensitivity of the Amerlite kit was given s "better
than 0.5 μ§/Ρ, that for the Abbott kit s "calculated
to be approximately 0.5 μ§/1". The results of this
study confirm the Abbott results and support the
Amersham Claims (see tab. 6 a & 6 c).
Table 6 b demonstrates once again, that kit Standards,
even though calibrated against the same international
reference material (here WHO 73/601), are not inter-
changeable. This is shown most dramatically for the
highest Amersham Standard (60 μg/l) which gave a
value of less than 0.5 μg/l when measured s sample
in the Abbott kit. This value was repeatedly obtained,
and so a mistake in the measurement itself can be
excluded. The question of a high dose hook effect
can be ruled out s sera with CEA levels above 1500
μg/l still gave an optical density reading in the Abbott
kit above that of the highest Standard (80 μg/l).
To conclude, it can be shown that both kits are similar
in performance, and that the luminescence enhanced
enzyme immunoassay kit from Amersham Inter-
national can take its place alongside other established
non-radioisotopic methods. However, like its compe-
titors, the luninescence enhanced enzyme immunoas-
say cannot be used s a "screening method", but only
in the follow-up and control of tumour patients.
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